1. Home
  2. CARE vs TRDA Comparison

CARE vs TRDA Comparison

Compare CARE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carter Bankshares Inc.

CARE

Carter Bankshares Inc.

N/A

Current Price

$20.11

Market Cap

438.9M

Sector

Finance

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$12.88

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CARE
TRDA
Founded
1974
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
438.9M
481.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CARE
TRDA
Price
$20.11
$12.88
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
159.0K
192.4K
Earning Date
04-30-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
30.19
N/A
EPS
1.38
N/A
Revenue
$20,315,000.00
$25,421,000.00
Revenue This Year
$12.50
$39.97
Revenue Next Year
$9.72
$53.29
P/E Ratio
$14.57
N/A
Revenue Growth
4.65
N/A
52 Week Low
$13.61
$4.93
52 Week High
$22.51
$13.66

Technical Indicators

Market Signals
Indicator
CARE
TRDA
Relative Strength Index (RSI) 35.78 57.31
Support Level $19.32 $9.78
Resistance Level $20.36 N/A
Average True Range (ATR) 0.60 0.91
MACD -0.17 0.14
Stochastic Oscillator 21.29 67.11

Price Performance

Historical Comparison
CARE
TRDA

About CARE Carter Bankshares Inc.

Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: